Menu
Not yet recruiting NCT05833620

Identification and Characterization of Genetic Variants in Hereditary Angioedema

Observational Hereditary Angioedema With C1 Esterase Inhibitor Deficiency

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Hereditary Angioedema With C1 Esterase Inhibitor Deficiency. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Spain
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Identification and Functional Characterization of Genetic Variants Associated With Specific Clinical Phenotypes in Hereditary Angioedema Due to C1 Inhibitor Deficiency: An Unbiased Approach

Overview

This project aims to analyse in an unbiased way the existence of genetic variants that contribute to explaining and predicting the differences in clinical expression between patients with HAE.

Primary outcome measures

  • Set of validated disease-modifying genetic variants in Spanish patients with HAE-C1INH [Time frame: Day 1]

Eligibility criteria

Inclusion criteria

  • Adult patients (≥ 18 years old) with HAE-C1INH diagnosis (confirmed by mutation in SERPING1 gen or immunochemical study showing a decrease in C1INH function <50% in two determinations together with a family history (symptomatic patients' group)
  • Patients ≥ 22 years old with C1INH hereditary deficiency (confirmed by mutation of SERPING1 gene or immunochemical study showing a decrease in C1INH function <50% in two determinations together with a family history) and who have not developed symptoms consistent with HAE-C1INH
  • Signed informed consent.

Exclusion criteria

  • No confirmed C1INH deficiency.
  • Inability to sign the informed consent.
  • Presence of recurrent angioedema with histaminergic characteristics (response to treatment with antihistamines, glucocorticoids and/or epinephrine)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Cohort

Study locations

Spain · 2 centers
  • Hospital Universitari Vall d'Hebron — Barcelona
  • Hospital Universitario La Paz — Madrid

Identifiers

NCT: NCT05833620 · GENOMAEH_01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗